PY-314

N/A

Report date: 2024/03/24 20:00:35

Base Information

Drug NamePY-314
Drug Alias NamePY-314PY314
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTriggering receptor expressed on myeloid cells 2 inhibitors
TargetsTriggering receptor expressed on myeloid cells 2
Therapy Area/IndicationsSolid tumoursGenital Neoplasms, FemaleOvarian Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCentre for the Commercialization of Antibodies and Biologics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFoundery Immune Studio LLCAbcam PLCIkena Oncology Inc +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursGenital Neoplasms, FemaleOvarian Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A